IBDEI0ND ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11498,1,1,0)
 ;;=1^441.9
 ;;^UTILITY(U,$J,358.3,11498,1,2,0)
 ;;=2^ANEURYSM,AORTIC W/O RUPTURE
 ;;^UTILITY(U,$J,358.3,11498,2)
 ;;=^9277
 ;;^UTILITY(U,$J,358.3,11499,0)
 ;;=442.9^^76^755^3
 ;;^UTILITY(U,$J,358.3,11499,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11499,1,1,0)
 ;;=1^442.9
 ;;^UTILITY(U,$J,358.3,11499,1,2,0)
 ;;=2^ANEURYSM,NON-AORTIC
 ;;^UTILITY(U,$J,358.3,11499,2)
 ;;=^7390
 ;;^UTILITY(U,$J,358.3,11500,0)
 ;;=710.3^^76^755^4
 ;;^UTILITY(U,$J,358.3,11500,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11500,1,1,0)
 ;;=1^710.3
 ;;^UTILITY(U,$J,358.3,11500,1,2,0)
 ;;=2^DERMATOMYOSITIS
 ;;^UTILITY(U,$J,358.3,11500,2)
 ;;=^33162
 ;;^UTILITY(U,$J,358.3,11501,0)
 ;;=446.5^^76^755^5
 ;;^UTILITY(U,$J,358.3,11501,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11501,1,1,0)
 ;;=1^446.5
 ;;^UTILITY(U,$J,358.3,11501,1,2,0)
 ;;=2^GIANT CELL ARTERITIS
 ;;^UTILITY(U,$J,358.3,11501,2)
 ;;=^117658
 ;;^UTILITY(U,$J,358.3,11502,0)
 ;;=446.20^^76^755^6
 ;;^UTILITY(U,$J,358.3,11502,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11502,1,1,0)
 ;;=1^446.20
 ;;^UTILITY(U,$J,358.3,11502,1,2,0)
 ;;=2^HYPERSENSITIVITY ANGIITIS, UNS
 ;;^UTILITY(U,$J,358.3,11502,2)
 ;;=^60279
 ;;^UTILITY(U,$J,358.3,11503,0)
 ;;=446.3^^76^755^7
 ;;^UTILITY(U,$J,358.3,11503,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11503,1,1,0)
 ;;=1^446.3
 ;;^UTILITY(U,$J,358.3,11503,1,2,0)
 ;;=2^LETHAL MIDLINE GRANULOMA
 ;;^UTILITY(U,$J,358.3,11503,2)
 ;;=^52905
 ;;^UTILITY(U,$J,358.3,11504,0)
 ;;=446.1^^76^755^8
 ;;^UTILITY(U,$J,358.3,11504,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11504,1,1,0)
 ;;=1^446.1
 ;;^UTILITY(U,$J,358.3,11504,1,2,0)
 ;;=2^MUCOCUTANEOUS LYMPH SYND (MCLS)
 ;;^UTILITY(U,$J,358.3,11504,2)
 ;;=^79494
 ;;^UTILITY(U,$J,358.3,11505,0)
 ;;=443.9^^76^755^12
 ;;^UTILITY(U,$J,358.3,11505,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11505,1,1,0)
 ;;=1^443.9
 ;;^UTILITY(U,$J,358.3,11505,1,2,0)
 ;;=2^PERIPH VASCULAR DIS NOS
 ;;^UTILITY(U,$J,358.3,11505,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,11506,0)
 ;;=446.0^^76^755^13
 ;;^UTILITY(U,$J,358.3,11506,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11506,1,1,0)
 ;;=1^446.0
 ;;^UTILITY(U,$J,358.3,11506,1,2,0)
 ;;=2^POLYARTERITIS NODOSA
 ;;^UTILITY(U,$J,358.3,11506,2)
 ;;=^91874
 ;;^UTILITY(U,$J,358.3,11507,0)
 ;;=710.4^^76^755^14
 ;;^UTILITY(U,$J,358.3,11507,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11507,1,1,0)
 ;;=1^710.4
 ;;^UTILITY(U,$J,358.3,11507,1,2,0)
 ;;=2^POLYMYOSITIS
 ;;^UTILITY(U,$J,358.3,11507,2)
 ;;=^186822
 ;;^UTILITY(U,$J,358.3,11508,0)
 ;;=452.^^76^755^15
 ;;^UTILITY(U,$J,358.3,11508,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11508,1,1,0)
 ;;=1^452.
 ;;^UTILITY(U,$J,358.3,11508,1,2,0)
 ;;=2^PORTAL VEIN THROMBOSIS
 ;;^UTILITY(U,$J,358.3,11508,2)
 ;;=^269815
 ;;^UTILITY(U,$J,358.3,11509,0)
 ;;=714.2^^76^755^16
 ;;^UTILITY(U,$J,358.3,11509,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11509,1,1,0)
 ;;=1^714.2
 ;;^UTILITY(U,$J,358.3,11509,1,2,0)
 ;;=2^RHEUMATOID ARTHRITIS,SYSTEMIC
 ;;^UTILITY(U,$J,358.3,11509,2)
 ;;=^272111
 ;;^UTILITY(U,$J,358.3,11510,0)
 ;;=135.^^76^755^17
 ;;^UTILITY(U,$J,358.3,11510,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11510,1,1,0)
 ;;=1^135.
 ;;^UTILITY(U,$J,358.3,11510,1,2,0)
 ;;=2^SARCOIDOSIS
 ;;^UTILITY(U,$J,358.3,11510,2)
 ;;=^107916
 ;;^UTILITY(U,$J,358.3,11511,0)
 ;;=710.0^^76^755^18
 ;;^UTILITY(U,$J,358.3,11511,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11511,1,1,0)
 ;;=1^710.0
 ;;^UTILITY(U,$J,358.3,11511,1,2,0)
 ;;=2^SYST LUPUS ERYTHEMATOSIS
 ;;^UTILITY(U,$J,358.3,11511,2)
 ;;=^72159
 ;;^UTILITY(U,$J,358.3,11512,0)
 ;;=710.1^^76^755^19
